Feminine Intimate Care OEM for the Philippines: FDA Cosmetic Notification Guide
The Philippines FDA runs one of the fastest cosmetic notification systems in Southeast Asia — but the LTO-first rule, selectable CPN validity, and the no-advertising-before-CPN rule catch many importers off guard. This guide walks private-label importers through the Certificate of Product Notification (CPN) process for feminine intimate care, the document package, and the red lines that force products out of the cosmetics category.
For B2B buyers sourcing feminine intimate care private label for the Philippine market: cosmetics there are regulated by the FDA Philippines Center for Cosmetics Regulation and Research (CCRR) under the ASEAN Cosmetic Directive, through a pre-market notification system. The deliverable is a Certificate of Product Notification (CPN) with an NN number — and without one, your product cannot be legally manufactured, imported, sold, distributed, promoted or advertised in the Philippines.
The most common sourcing mistake is treating the CPN like a registration formality. In practice the LTO-first rule decides everything: a Philippine-based company must hold a License to Operate before a single notification can be filed, and the entire document chain starts with that local holder.
Who this guide is for: Brand owners, importers, procurement managers and product developers planning Philippine launches of feminine intimate-care washes, foams, serums, sprays and wellness products.
1. Why the Philippines Is the Next ASEAN Gate
The Philippines fully implemented the ASEAN Cosmetic Directive in 2008 and regulates cosmetics under Republic Act No. 9711 (FDA Act of 2009) and Administrative Order No. 2016-0007. Feminine intimate-care products are classified as cosmetics under ACD Annexes, and the route to market is a pre-market notification — not drug pre-approval.
Three structural facts matter to B2B buyers planning entry:
- Notification is fast but local-only. FDA review typically runs 3-10 working days for complete files, yet foreign manufacturers can never file directly — a Philippine company with an LTO is mandatory.
- The CPN has a built-in expiration. Validity is selected at application (typically 1, 2 or 3 years), and revalidation must land on or before the validity date. An expired CPN cannot be revalidated — it becomes a new application, and any formula or label change does too.
- Advertising is locked until the CPN exists. No promotion of any kind — social media, e-commerce listings, flyers — is allowed before a valid CPN is issued.
2. How Philippines FDA Cosmetic Notification Works
The process sits entirely inside the FDA e-Portal (Cosmetic e-Notification system, also referred to as e-COS), run by the CCRR under the FDA Philippines. The foreign brand or OEM does not hold the account — the local Philippine Responsible Person does.
| Element | Philippine Requirement |
|---|---|
| Governing law | RA 9711 (FDA Act of 2009) + AO 2016-0007 + ASEAN Cosmetic Directive |
| System type | Pre-market notification (not registration/approval) |
| Deliverable | Certificate of Product Notification (CPN) with NN number |
| Filing channel | FDA e-Portal / e-COS, CCRR account held by the local Responsible Person |
| Local party | Philippine-based company with a valid License to Operate (LTO) |
| Typical review | 3-10 working days for complete files |
| Government fee | About PHP 500 per product |
| Validity | Selectable at application — typically 1, 2 or 3 years |
3. The LTO-First Rule: You Cannot File Without a Local Holder
This is the single most important sequencing rule in the Philippines. The foreign OEM and the brand owner are document suppliers; the actual applicant is a Philippine-licensed entity. Concretely:
- Secure the local partner first. Importers, distributors or licensed third-party agents with a valid FDA Philippines LTO for cosmetics are the only entities that can hold the CCRR account and file notifications.
- Execute a notarized Letter of Authorization (LOA) / Power of Attorney (POA). The foreign manufacturer authorizes the Philippine holder to act for the brand; depending on origin-country rules, the POA must be authenticated or consularized.
- Build the whole plan around the LTO timeline. If the partner does not yet hold an LTO, that license becomes your critical path before any CPN can be submitted.
Because every other step depends on this holder, B2B buyers should qualify the Philippine partner's LTO status and notification track record before shortlisting the OEM — not after.
4. The Document Package for a CPN Application
Almost every CPN requirement resolves back to the OEM's file. The documents below come almost entirely from the factory side, assembled under the Philippine holder:
| Document | What the Philippine FDA Looks For |
|---|---|
| Full INCI ingredient list | INCI names, CAS numbers, function and exact percentages totaling 100%; ACD Annex compliance |
| Product specification sheet | Physical/chemical characteristics: appearance, color, odor, pH, viscosity |
| Certificate of Analysis (COA) | Microbial and heavy metal (lead, arsenic, mercury) results per batch, within ASEAN limits |
| CPSR safety assessment | Product Safety Assessment Report signed by a qualified toxicologist |
| GMP / ISO 22716 evidence | Valid certificate for the manufacturing facility |
| Certificate of Free Sale (CFS) | From the country of origin, authenticated/consularized as applicable |
| LOA / POA chain | Clear authorization from manufacturer or brand owner to the Philippine holder |
| PIF package | Part I administrative, Part II quality/specs, Part III safety, Part IV GMP documentation |
| Label artwork | 1:1 design or physical photos showing all mandatory label elements |
Non-English documents need certified English translations. Sticker labeling is allowed for imported items, but the sticker must carry every mandatory element accurately.
5. Labeling & Claims Red Lines in the Philippines
Labels must be in English or Filipino and include the product name and function, the full INCI list in descending order, net content, manufacturer name and address, country of origin, the Philippine Responsible Person's name and address, batch/lot number, manufacturing and expiry dates (for shelf life under 30 months), warnings, directions for use, and the CPN number.
Claims are where intimate-care products most often slip out of the cosmetics category. The Philippines FDA treats any medicinal, therapeutic or disease-related claim as a drug matter, which forces the product out of the notification route and into drug, OTC or medical-device registration. For feminine intimate care, the practical consequences are direct:
- No treatment claims. Wording that implies curing, treating or preventing a condition — including antibacterial or antifungal disease language — moves the product outside cosmetics.
- No anti-acne / medical whitening positioning. Products positioned as acne treatments or melasma treatments face drug classification.
- No advertising before CPN. Social media, e-commerce listings and flyers are all covered — promote only after the valid CPN is issued, and keep every claim consistent with the FDA-submitted label.
- Watch prohibited ingredients. Hydroquinone, steroids, tretinoin and mercury are prohibited; DEET was added under the March 2025 ACD revision, with adjusted limits for zinc pyrithione and salicylic acid.
6. Step-by-Step Filing Workflow
| Step | Action | Owner |
|---|---|---|
| 1 | Confirm the Philippine partner holds a valid FDA LTO for cosmetics | Local partner |
| 2 | Lock the OEM document set: INCI, specs, COA, CPSR, GMP/ISO, CFS, POA | OEM + brand |
| 3 | Prepare label artwork with all mandatory elements, English or Filipino | Brand + OEM |
| 4 | Compile the PIF in four parts under the Philippine holder | Local partner |
| 5 | File the CPN in the FDA e-Portal / e-COS with the selected validity term | Local partner |
| 6 | Track review (typically 3-10 working days); answer any FDA clarifications | Local partner |
| 7 | Receive the CPN with NN number; put the NN number on the label before sale | Local partner |
| 8 | Maintain PIF and adverse-event reporting; calendar the revalidation deadline | Local partner |
7. Common Rejection Reasons
| Rejection Cause | How to Avoid It |
|---|---|
| No valid LTO at filing time | Confirm the Philippine holder's LTO before the project starts |
| INCI percentages not totaling 100% | Require an exact, reconciled ingredient declaration from the OEM |
| COA outside ASEAN heavy-metal limits | Specify microbial and lead/arsenic/mercury testing at RFQ stage |
| CPSR not signed by a qualified toxicologist | Use a PIF/CPSR pack that includes a qualified safety assessor |
| Treatment or disease claim on label or marketing | Keep claims gentle, non-medical and consistent with the filed label |
| CFS not authenticated / consularized | Start CFS notarization early with the country-of-origin authority |
| Revalidation filed after the validity date | Calendar the deadline; an expired CPN means a new application |
| Product changed after CPN issued | Any formula, labeling or claim change is a new CPN application |
8. How to Evaluate an OEM Partner for the Philippines
When shortlisting OEM factories for a Philippine launch, map the questions directly to the CPN document chain:
| Evaluation Area | What to Ask | Why It Matters |
|---|---|---|
| GMP / ISO standing | Do you hold valid ISO 22716-aligned / GMP evidence? | A required attachment in the CPN file |
| Test completeness | Do you supply batch COA with heavy metals and microbials? | ASEAN-limit compliance is a top rejection cause |
| Safety assessment | Is a qualified toxicologist on your PIF/CPSR package? | CPSR must be signed by a qualified safety assessor |
| Claim discipline | Can you keep feminine intimate-care claims non-medical? | Medicinal wording forces drug classification |
| Document readiness | Is the Philippine document set kept on file, not assembled per request? | Shortens your LTO-to-CPN critical path |
| MOQ & lead time | Can you start with a flexible batch and hit a 30-60 working-day lead time? | Protects your first-market validation |
How Zhongkang Bainian lines up
Zhongkang Bainian Life Science Technology Co., Ltd. is a dual-track OEM/ODM manufacturer serving intimate care and personal wellness private label. For Philippines-market projects:
| Requirement | Our Capability |
|---|---|
| Production compliance | ISO 22716-aligned & GMP-aligned factory, 20,000 m² facility with 100K-class (ISO 8) clean workshop |
| Dual-track registration | Cosmetic filing (Min-Zhuang 20220008) + disinfectant product license ((Min) Wei-Xiao-Zheng-Zi (2021) No. 040036) |
| Test evidence | CMA-accredited reports (report No. wx24030093): batch COA, microbial, heavy metal, mucosal irritation |
| Philippine document set | INCI reconciliation, COA, specs, PIF/CPSR support and POA chains assembled on project confirmation |
| MOQ & lead time | Flexible MOQ from 500 kg liquid per batch; samples in 7 working days; production 30-60 working days |
| Track record | 37+ years manufacturing heritage, 27+ years OEM/ODM expertise, trusted by 1,000+ brands across 12+ countries |
FAQ: Philippines FDA CPN for Feminine Intimate Care
Do I need a Philippine License to Operate before filing a CPN?
Yes. A Philippine-based company must hold a valid License to Operate (LTO) from the FDA Philippines and act as the local Responsible Person before any cosmetic product notification is filed. Foreign manufacturers and brand owners cannot file a CPN directly.
How long is a Philippine cosmetic CPN valid, and can it be renewed?
The CPN validity is selected at application, typically 1, 2 or 3 years. Revalidation must be submitted on or before the validity date with payment. An expired CPN cannot be revalidated — you must file a new CPN application, and any formula, labeling or claim change also counts as a new application.
Can I advertise my feminine intimate care product before the CPN is issued?
No. No advertising or promotion is allowed before a valid Certificate of Product Notification is obtained — this covers social media, e-commerce listings, flyers, TV and outdoor ads. All marketing claims must be true, non-misleading and consistent with the label information submitted to the FDA.
What happens if my CPN expires?
An expired CPN cannot be revalidated under FDA Advisory No. 2023-1160 — you must file a new CPN application, and the product cannot be legally manufactured, imported, sold, distributed, promoted or advertised without a valid CPN. Keep revalidation deadlines on a compliance calendar.
Planning a Philippine launch? Ask our OEM team for the CPN document package and a market-entry review for your feminine intimate-care line.
*This guide is for informational purposes only. Regulatory requirements vary by market and over time. Always consult with the FDA Philippines Center for Cosmetics Regulation and Research (CCRR) and with your appointed Philippine local representative before finalizing product specifications, documentation and launch timelines.*
